Remitting–relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab

Bone marrow transplantation (BMT) was introduced as a treatment option 15 years ago for severe, drug-resistant multiple sclerosis (MS). Up until now, BMT has been undertaken in relatively few patients worldwide, with moderate success, and recent studies suggest that patients with early, highly aggre...

Descripción completa

Detalles Bibliográficos
Autores principales: Mouzaki, Athanasia, Koutsokera, Maria, Dervilli, Zoe, Rodi, Maria, Kalavrizioti, Dimitra, Dimisianos, Nikolaos, Matsoukas, Ioannis, Papathanasopoulos, Panagiotis
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962327/
https://www.ncbi.nlm.nih.gov/pubmed/21042570
http://dx.doi.org/10.2147/IJGM.S13648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962327/
https://www.ncbi.nlm.nih.gov/pubmed/21042570
http://dx.doi.org/10.2147/IJGM.S13648

Ejemplares similares